Sakiyama Ryoichi, Blau Brandon J, Miki Toshio
Ryoichi Sakiyama, Brandon J Blau, Toshio Miki, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States.
World J Gastroenterol. 2017 Mar 21;23(11):1974-1979. doi: 10.3748/wjg.v23.i11.1974.
There is currently a pressing need for alternative therapies to liver transplantation. The number of patients waiting for a liver transplant is substantially higher than the number of transplantable donor livers, resulting in a long waiting time and a high waiting list mortality. An extracorporeal liver support system is one possible approach to overcome this problem. However, the ideal cell source for developing bioartificial liver (BAL) support systems has yet to be determined. Recent advancements in stem cell technology allow researchers to generate highly functional hepatocyte-like cells from human pluripotent stem cells (hPSCs). In this mini-review, we summarize previous clinical trials with different BAL systems, and discuss advantages of and potential obstacles to utilizing hPSC-derived hepatic cells in clinical-scale BAL systems.
目前迫切需要肝脏移植的替代疗法。等待肝脏移植的患者数量大大高于可用于移植的供体肝脏数量，导致等待时间长且等待名单上的死亡率高。体外肝脏支持系统是克服这一问题的一种可能方法。然而，开发生物人工肝（BAL）支持系统的理想细胞来源尚未确定。干细胞技术的最新进展使研究人员能够从人类多能干细胞（hPSC）中生成功能高度健全的肝细胞样细胞。在本综述中，我们总结了不同BAL系统的既往临床试验，并讨论了在临床规模的BAL系统中使用hPSC来源的肝细胞的优势和潜在障碍。
